vTv Therapeutics Inc. (NASDAQ:VTVT) Sees Significant Decrease in Short Interest

vTv Therapeutics Inc. (NASDAQ:VTVT) was the recipient of a significant decline in short interest during the month of March. As of March 31st, there was short interest totalling 16,100 shares, a decline of 34.3% from the March 15th total of 24,500 shares. Approximately 1.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 22,400 shares, the days-to-cover ratio is presently 0.7 days.

vTv Therapeutics Stock Up 1.3 %

VTVT opened at $18.82 on Thursday. The firm has a market capitalization of $60.04 million, a P/E ratio of -4.15 and a beta of 0.81. The stock has a fifty day moving average of $18.03 and a 200-day moving average of $15.86. vTv Therapeutics has a 12-month low of $12.12 and a 12-month high of $29.19.

vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings data on Thursday, March 20th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.32. The business had revenue of $0.02 million during the quarter.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on VTVT shares. StockNews.com started coverage on vTv Therapeutics in a research note on Wednesday. They set a “sell” rating for the company. HC Wainwright initiated coverage on shares of vTv Therapeutics in a research note on Wednesday, April 9th. They set a “buy” rating and a $36.00 price objective for the company.

Institutional Trading of vTv Therapeutics

A hedge fund recently bought a new stake in vTv Therapeutics stock. JPMorgan Chase & Co. bought a new stake in shares of vTv Therapeutics Inc. (NASDAQ:VTVT) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 1,803 shares of the biotechnology company’s stock, valued at approximately $25,000. JPMorgan Chase & Co. owned 0.06% of vTv Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 17.51% of the company’s stock.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.